VBI Vaccines, Inc. – (NASDAQ:VBIV)’s share price was up 5.3% during trading on Thursday . The stock traded as high as $3.80 and last traded at $3.77, with a volume of 63,884 shares. The stock had previously closed at $3.58.

Separately, Ladenburg Thalmann started coverage on shares of VBI Vaccines, Inc. – in a report on Tuesday. They issued a “buy” rating on the stock.

The firm’s market cap is $123.59 million. The stock has a 50 day moving average price of $3.90 and a 200-day moving average price of $3.95.

An institutional investor recently bought a new position in VBI Vaccines, Inc. – stock. Cambridge Investment Research Advisors Inc. bought a new position in VBI Vaccines, Inc. – (NASDAQ:VBIV) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 1,433,100 shares of the biopharmaceutical company’s stock, valued at approximately $3,497,000. Cambridge Investment Research Advisors Inc. owned approximately 6.09% of VBI Vaccines, Inc. – as of its most recent filing with the SEC.

VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.